Efficacy and safety of linaclotide in treatment‐resistant chronic constipation: A multicenter, open‐label study
The study was conducted in an older adult population, similar to real clinical practice. Linaclotide may be an option for treating CC that shows an inadequate response to conventional therapy.
Authors
- Atsushi Nakajima (ORCID: https://orcid.org/0000-0002-6263-1436)
- Hidenori Ohkubo (ORCID: https://orcid.org/0000-0002-7367-6402)
- Izuru Terada
- Takuma Higurashi (ORCID: https://orcid.org/0000-0002-1815-4396)
- Noboru Misawa (ORCID: https://orcid.org/0000-0002-9272-174X)
- Tsutomu Yoshihara (ORCID: https://orcid.org/0000-0001-5150-7942)
- Michihiro Iwaki (ORCID: https://orcid.org/0000-0002-7650-0699)
- Keiichi Ashikari (ORCID: https://orcid.org/0000-0001-8379-4704)
- Tomohiro Takatsu (ORCID: https://orcid.org/0000-0001-7686-599X)
- Takeo Kurihashi
- Takaomi Kessoku (ORCID: https://orcid.org/0000-0002-5587-1386)
- Akiko Fuyuki (ORCID: https://orcid.org/0000-0003-1587-6980)
- Machiko Nakatogawa (ORCID: https://orcid.org/0000-0003-3145-0314)
- Masataka Morita
- Yusuke Tanaka (ORCID: https://orcid.org/0000-0002-3987-1589)
- Koji Yamamoto
Institutions
- Astellas Pharma (Japan) (JP)
- Tokyo Medical University (JP)
- Yokohama City University Hospital (JP)
- Kanagawa Dental University (JP)
- International University of Health and Welfare (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Neurogastroenterology & Motility
- Published
- 2024-10-06
- DOI
- https://doi.org/10.1111/nmo.14938
- Citations
- 4
- Primary Topic
- Gastrointestinal motility and disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.86
Funders
- Astellas Pharma